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Abstract
Background: Erythropoietin (EPO) has been suggested to promote cardiac repair after MI. However, the
randomized, double-blind, placebo controlled REVIVAL-3 trial showed that short term high dose EPO in timely
reperfused myocardium does not improve left ventricular ejection fraction after 6 months. Moreover, the study
raised safety concerns due to a trend towards a higher incidence of adverse clinical events as well as a increase in
neointima formation after treatment with EPO. The present study therefore aimed to assess the 5-year clinical
outcomes.
Methods: After successful reperfusion 138 patients with STEMI were randomly assigned to receive epoetin
beta (3.33×104 U, n = 68) or placebo (n = 70) immediately, 24 and 48 h after percutaneous coronary intervention. The
primary outcome of the present study- the combined incidence of MACE 5 years after randomization - occurred in
25% of the patients assigned to epoetin beta and 17% of the patients assigned to placebo (RR 1.5; 95% CI 0.8-3.5; p = 0.
26). Target lesion revascularization was required in 15 patients (22.1%) treated with epoetin-ß and 9 patients (12.9%)
treated with placebo (p = 0.15). Analysis of patients in the upper and lower quartile of baseline hemoglobin as an
indirect estimate of endogenous erythropoietin levels revealed no significant impact of endogenous erythropoietin on
efficiency of exogen administered epoetin-ß in terms of death and MACE.
Conclusion: These long-term follow-up data show that epoetin beta does not improve clinical outcomes of patients
with acute myocardial infarction.
Trial registration: URL www.clinicaltrials.gov; Unique identifier NCT00390832; trial registration date October 19th 2006
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Background
Despite continually improved treatment regimens the
rate of death and heart failure is still substantially high
after ST-elevation myocardial infarction (STEMI) [1–3].
The extent of myocardial necrosis is a main predictor
of mortality and morbidity after STEMI. Cardiac necro-
sis is not only determined by the myocardial ischemia it-
self, but also driven by secondary damage upon
reperfusion, the ischemia-reperfusion-injury. While the
ischemia-induced necrosis can effectively be treated by
timely myocardial reperfusion using percutaneous cor-
onary intervention (PCI), reperfusion-induced necrosis
is still barely preventable [4].
Erythropoietin (Epo), a hypoxia induced hormone, has
been shown to play a cardioprotective role in various
experimental models of myocardial ischemia and
ischemia-reperfusion via pleiotropic actions [5]. Besides
stimulation of haematopoesis, Epo induces mobilization
of endothelial progenitor cells and promotes neovascu-
larization and angiogenesis [6, 7]. It also exhibits anti-
apoptotic, anti-inflammatory and anti-oxidative properties
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in the heart [5], where cardiomyocytes and endothelial
cells express functional Epo receptors [8, 9].
However, despite promising results of experimental
and preclinical studies, we -like most other clinical tri-
als- showed in the randomized, double-blind, placebo
controlled REVIVAL-3 trial, that short-term, high dose
epoetin beta in addition to successful PCI in STEMI
does neither reduce infarct size nor improve left ven-
tricular function at 6 months [10–12]. On the contrary
we observed a trend towards a higher incidence of ad-
verse clinical events 6 month after epoetin beta treat-
ment as well as a significant increase in neointima
formation in the erythropoietin group [13]. This raises
safety concerns about the use of erythropoietin in pa-
tients with acute MI. By promoting neointima formation
and imparing arterial healing, erythropoietin might affect
clinical outcomes of STEMI patients over the longer
term. Moreover legacy or memory effects can influence
clinical prognosis even long after cessation of drug ad-
ministration [14]. However clinical outcome data more
than 12 month after erythropoietin therapy have never
been reported in patients treated for myocardial infarc-
tion. Thus, the aim of the present trial was to assess the
impact of high-dose, short term erythropoietin on long-
term clinical outcomes in STEMI patients. For this pur-
pose we extended the follow up of the REVIVAL-3 trial,
which compared 3 daily IV doses of 33,000 I.U. of rhE-
poetin beta administered immediately, 24 and 48 h after
PCI in STEMI to placebo treatment, up to 5 years.
Methods
Patients and protocol
The detailed study design and main results from the
REVIVAL-3 trial have been published previously [10]. In
brief, the REVIVAL-3 study was a prospective, random-
ized, double-blind, placebo-controlled trial allocating pa-
tients with acute STEMI in a 1:1 ratio after successful
primary PCI to medical treatment with either epoetin
beta or placebo as a supplement to treatment according
to guidelines.
To be included patients had to present with a first
STEMI within 24 h of symptom onset and had to have an
angiographic left ventricular ejection fraction (LVEF) of less
than 50% by visual estimation in the angiogramm. The
study drug was given immediately after successful PCI in
the catheterization laboratory as well as 24 and 48 h after
randomization. Each time, patients received either 3.33 ×
104 IU of recombinant human epoetin-β (NeoRecormon;
F. Hoffmann-La Roche, Basel, Switzerland) or a matching
placebo intravenously for 30 min. The periprocedural anti-
thrombotic therapy consisted of 600 mg of clopidogrel or-
ally, 500 mg aspirin, and unfractionated heparin with or
without abciximab intravenously. Heparin was given as a
bolus of 140 IU or 70 IU in case of additional abciximab
(0.25 mg/kg body weight bolus, followed by an infusion of
0.125 μg/kg per min for 12 h). Postinterventional all pa-
tients recieved clopidogrel 75 mg twice a day for 3 days
followed by 75 mg/d for at least 6 months. Aspirin 100 mg
twice a day was recommended indefinitely.
The study protocol was approved by the institutional
ethics committee and all patients gave written informed
consent for participation in the study. The study has
been registered in clinicaltrials.gov (NCT00390832).
One hundred thirty-eight patients were randomized,
from January 2007 to November 2008 at the Deutsches
Herzzentrum and 1st Medizinische Klinik rechts der
Isar, to epoetin-ß (n = 68) or placebo (n = 70) and finally
included in the present extended follow up study.
Clinical follow-up
The pre-specified primary end point of the main
REVIVAL-3 trial was LVEF 6 months after random as-
signment measured by MRI. Other end points included
infarct size at 5 days and 6 months and clinical adverse
events (death, recurrent myocardial infarction, stroke,
and infarct-related artery revascularization) at 30 days
and 6 months.
Epoetin did not improve LVEF or reduce infarct size at
6 months follow up. On the contrary, there was a trend
toward a higher adverse event rate with erythropoietin
at 6 months.
The primary outcome of interest for the current ana-
lysis was the combined incidence of major adverse car-
diac events (MACE), including death, recurrent MI,
stroke, coronary bypass surgery (ACVB) and target ves-
sel revascularistion, 5 years after randomization. The in-
cidence of the individual components of the primary end
point was also assessed. Information on vital status, re-
current MI, target vessel revascularization and stroke
was collected by annual telephone interviews and from
hospital records. In case the patients reported cardiac
symptoms during the interview, complete clinical, elec-
trocardiogram, and laboratory examination was per-
formed in the outpatient clinic or by the referring
physician. Reinfarction was defined as the onset of re-
current symptoms of ischemia combined with new ST-
segment elevations and/or a second increase of serum
CK or CK-MB to at least twice the upper limit of the
normal range. Target vessel revascularization was de-
fined as PCI or bypass grafting of the infarct-related cor-
onary artery after primary PCI.
Statistical analysis
All data were analyzed on the basis of the intention-
to-treat principle using data from all patients as ran-
domized. Categorical data are presented as counts or
proportions (%). Continuous data are presented as
mean ± standard deviation. Differences between the
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groups were assessed using χ2 or Fisher exact test for
categorical data and t test for continuous data. The
cumulative incidence of the composite end point dur-
ing the 5-year–follow up was evaluated with the
Kaplan Meier method. Survival free of adverse events
was defined as the interval from randomization until
the event of interest. Data for patients who did not
have an event of interest were censored at the date of
the last follow-up. The difference in the composite
event rate between the 2 study groups was checked
for significance by means of a Cox proportional haz-
ards model, which also allowed the calculation of the
respective hazard ratio with its 95% confidence inter-
val. A 2-tailed probability value < 0.05 was considered
to indicate statistical significance. All analyses were
performed using S-plus statistical package (S-PLUS,
In- sightful Corp., Seattle, Washington).
Results
All 138 patients enrolled in the REVIVAL-3 trial were
included in the present extend follow up study. All had
received the randomly assigned medication: 68 epoetin-
ß and 70 placebo. One hundred thirty-four patients
(97%) completed the 5-years follow up, while 4 patients
were lost to follow up. Detailed baseline characteristics
of the patients have been published previously and were
similarly distributed in the two treatment groups. Table 1
summarizes some key data of the study population.
The mean age of the patients was 59.1 (±13.0) years in
the epoetin-ß group and 62.1 (±12.3) years in the control
group, with a proportion of males of 82% versus 74%.
The median time from symptom onset to PCI was 252
(interquartile range 175–413) minutes in patients receiv-
ing epoetin-ß and 253 (interquartile range 165–457) mi-
nutes in patients in the control group. Baseline
angiographic LVEF was 46% in both groups, indicating
substantial myocardial infarction. The majority of pa-
tients presented with multi-vessel-disease (62% versus
71%) and was treated with drug-eluting stents (93% ver-
sus 95%). Although epoetin-ß induced an increase in cir-
culating reticulocytes 5 days after random assignment
(11.3 ± 3.8×104/μl versus 10.9 ± 4.18×104/μl; p = 0.563 to
34.2 ± 9.58×104/μl versus 16.8 ± 6.58×104/μl; p = 0.001)
and a rise in the maximal platelet count (265 ± 70×109/l
versus 232 ± 74×109/l, P = 0.011), it was not associated
with a rise in maximal hemoglobin levels (14.8 ± 1.6 mg/
dl versus 15 ± 1.3 mg/dl, P = 0.593).
Clinical outcome
Table 2 summarizes the major clinical events registered
after hospital discharge in both patient groups over the
extended follow-up. A total of 14 patients (10%) died
during the 5-years study period, 8 (11.8%) in the epoe-
tin-ß and 6 (8.6%) in the control group (p = 0.53; Fig. 1a).





Age, mean y (±SD) 59.1 (13.0) 62.1 (12.3)
Women, n(%) 12 (18) 18 (26)
Body mass index, mean (±SD) 28 (4) 27 (4)
Diabetes, n(%) 11 (16) 10 (14)
Current smoker, n(%) 29 (43) 30 (43)
Multivessel disease, n(%) 42 (62) 50 (71)
Angiographic LVEF, mean % (±SD) 46 (8) 46 (8)
Infarct related coronary artery, n(%)
LAD 34 (50) 31 (44)
RCA 19 (33.9) 18 (31.0)
LCX 7 (12.5) 12 (20.7)
LMCA 0 1 (1)
Initial TIMI flow grade, n(%)
0 35 (52) 41 (59)
1 11 (16) 11 (14)
2 20 (29) 15 (21)
3 2 (3) 4 (6)
Final TIMI flow grade, n(%)
1 0 1 (1)
2 5 (7) 6 (9)
3 63 (93) 63 (90)
Type of intervention, n(%)
Bare metal stent 3 (4) 3 (4)
Drug-eluting stent 63 (93) 66 (95)
Balloon angioplasty 2 (3) 1 (1)
Creatine kinase-MB max, U/L (range) 201 (121–450) 213 (124–312)
Symtom onset to PCI, min (range) 252 (175–413) 253 (165–457)
Hemoglobin max, mean g/dl (±SD) 14.8 (1.6) 15 (1.3)
Table 2 Summary of major clinical events registered after






Death; n(%) 8 (11.8) 6 (8.6) p = 0.53
MI; n(%) 4 (5.9) 2 (2.9) p = 0.38
Death or MI; n(%) 10 (14.7) 7 (10.0) p = 0.40
Stroke; n(%) 1 (1.5) 0 (0) p = 0.31
Death or MI or Stroke; n(%) 10 (14.7) 7 (10.0) p = 0.40
Coronary bypass surgery; n(%) 1 (1.5) 0 (0) p = 0.31
Target lession revascularization; n(%) 15 (22.1) 9 (12.9) p = 0.15
MACE; n(%) 17 (25.0) 12 (17.1) p = 0.26
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While 2 epoetin-ß patients and 3 placebo patients had
died during the initial 6 month follow up, 6 patients re-
ceiving epoetin-ß and 3 patients receiving placebo died
between 6 month and 5 years. Individual causes of death
are shown in Table 3.
Six patients (4.3%) experienced MI, 2 (2.9%) in the pla-
cebo and 4 (5.9%) in the epoetin-ß group. Only 1 (1.5%)
patient in the epoetin-ß group suffered a stroke (p =
0.31). Coronary bypass surgery was also needed in 1
(1.5%) epoetin-ß patient and none of the control patient
(p = 0.31). Target lesion revascularization was required
in 15 patients (22.1%) treated with epoetin-ß and 9 pa-
tients (12.9%) treated with placebo (p = 0.15).
Figure 1b and c show the cumulative event rates of
survival free of recurrent MI and survival free of recur-
rent MI and stroke.
The current primary outcome - the cumulative inci-
dence of MACE 5 years after randomization - occurred
in 25% (n = 17) of the patients assigned to epoetin-ß and
17% (n = 12) of the patients assigned to placebo (RR 1.5;
95% CI 0.8-3.5; p = 0.26; Fig. 1d).
To analyze if elevated endogenous erythropoietin
levels might have interfered with effects of exogenous
administered epoetin-ß, we stratified the patients ac-
cording to their hemoglobin level on admission. Since
serum erythropoietin levels rise in an exponential man-
ner with a decrease in hemoglobin levels [15], we ana-
lyzed clinical outcome of patients in the lower (Hb <
14,1 g/dl) and the upper (Hb > 15,5 g/dl) quartile of
hemoglobin concentration on admission separately.
While the lower quartile consisted of 16 control patients
and 23 erythropoietin-treated patients, the upper quar-
tile comprised 34 patients, 19 treated by placebo and 15
by erythropoietin. During the 5 years follow up 1 death
in the placebo group and 5 deaths in the erythropoietin
group occurred in the lower Hb-quartile (Kaplan Meier
Fig. 1 Kaplan-Meier-Curves showing the cumulative event rates according to Epoetin beta therapy or Placebo. A Analysis of survival. B Analysis of
survival free of recurrent myocardial infarction (MI). C Analysis of survival free of recurrent MI and stroke. D Analysis of survival free of MACE
(recurrent MI, stroke and reintervention)
Table 3 Summary of patients who died during the 5 year
follow up period
Patient # Group Cause of death
1 Placebo cardiogenic shock
2 Placebo cardiogenic shock
3 EPO lung embolism
4 Placebo sudden cardiac death
5 EPO septic shock, stroke
6 EPO cancer
7 Placebo after orthopedic surgery
8 EPO sudden cardiac death
9 EPO unknown
10 Placebo cancer




Patient # 1–5 died 1–186 days after randomization. Patient # 7–14 died 187–
1860 days after randomization
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estimates of death: 6.2% placebo, 21.7% epoetin-ß; p =
0.19), whereas 2 control and none of the erythropoietin
patients experienced death in the upper Hb-quartile
(Kaplan Meier estimates of death: 10.5% placebo, 0%
epoetin-ß; p = 0.20). The cumulative incidence of MACE
5 years after randomization occurred in 21.7% (n = 5) of
the patients assigned to epoetin-ß and 18.8% (n = 3) of
the patients assigned to placebo in the lower hemoglobin
quartile (p = 0.82) and in 20% (n = 3) in epoetin-ß and
21.1% (n = 4) in placebo treated patients of the upper
quartile (p = 0.94).
Discussion
This extended follow-up of the REVIVAL-3 trial revealed
that high-dose, short-term epoetin-ß in addition to suc-
cessful PCI does not improve clinical long-term out-
comes of patients with acute myocardial infarction.
To the best of our knowledge, this is currently the
study with the longest follow up analyzing erythropoietin
effects in STEMI patients up to 5 years. All previous tri-
als focused on the first 6 month and to date only the
large HEBE III trial has provided one year follow up
results [16].
While most other trials have to deal with the problem
of a selective patient inclusion with small infarct sizes
the REVIVAL-3 trial only randomized large infarctions
affecting approximately 27–28% of the left ventricle with
impaired LV-Function [10]. This ensures, that erythro-
poietin effects have been tested in an adequate ischemic
condition.
Prognosis of patients with STEMI remains compli-
cated by a substantial number of death, reinfarction and
heart failure. According to real life registries like the
REAL register the 3-year cumulative incidence of death
is about 17. 5% and MACE about 22.9% in STEMI pa-
tients treated by timely PCI with DES (drug eluting
stents) [3]. Due to closely supervised and optimized
therapy in the setting of RCT (randomzied controlled
clinical trials) the present study has a somewhat lower
however still substantial 5-year cumulative incidence of
death (10%) and MACE (21%).
Since the extent of myocardial necrosis is a major de-
terminant of adverse postinfarction-outcome, therapies
able to further reduce infarct size are urgently needed.
According to experimental in vivo and ex-vivo studies
erythropoietin seemed to be such a promising candidate
by its angiogenic, anti-inflammatory, anti-hypertrophic
and anti-apoptotic properties [17]. It attenuated infarct
expansion and detrimental cardiac remodeling, reduced
infarct size and improved functional recovery in animal
models of ischemic cardiac injury [5]. However our re-
sults are in line with the majority of clinical studies and
recent meta-analyses, who all failed to demonstrate a
benefit for shortterm erythropoetin therapy in PCI-
treated STEMI patients in terms of both cardiac func-
tion and clinical prognosis [11, 18, 19]. A lot has been
speculated about this erythropoetin paradox - why the
overwhelming cardioprotective effects in animal studies
could not be translated into humans.
Animal experiments were conducted in two major ex-
perimental models, MI induced by permanent ligation of
a coronary artery or by temporary occlusion followed by
reperfusion. In the model of permanent occlusion animals
were mostly treated by a single intraperitoneal dose of
3000–5000 IU/kg of body weight erythropoietin immedi-
ately after ligation or even before [20, 21]. The best results
were achieved when EPO was applied at the time of occlu-
sion. Dose regimes in cardiac ischemia-reperfusion
worked also primarily with high doses of 2500–5000 IU/
kg of body weight erythropoietin intraperitoneal or intra-
venous and most regimes included a dose given even be-
fore ischemia was induced. Most effective results were
observed when treatment was applied no later than at the
time of reperfusion, i.e., 30–90 min from coronary occlu-
sion. In contrast the majority of clinical trials did not ad-
just the erythropoietin dose to the individual body weight,
in fact doses ranged between 30000–60000 IU, which cor-
responds to 430–860 IU/kg for a 70 kg patient. Drug ap-
plication was carried out between 6 to 48 h in average
after symptom onset [20, 21].
Therefore as a possible explanation of the
erythropoietin-paradox, mostly dosing and timing of
erythropoietin-administration has been supposed to be in-
appropriate, especially since experimental studies have
shown the existence of a dose-dependent therapeutic win-
dow of time subsequent to reperfusion [22]. Beyond this
window the erythropoietin induced tissue-protection is re-
duced or even abolished.
For example, Moon et al. showed in a rat model of
permanent coronary ligation, that erythropoietin medi-
ated cardioprotection with 3000 IU/kg of body weight
was still effective when administration was delayed up to
12 h after ischemic injury, but not if the treatment was
delayed for 24 h. With the lowest effective dose of
150 IU/kg of body weight beneficial effects were only
observed when administered within 4 h. This efficacy
was already lost when the administration was delayed by
8 h [23].
Our trial is among the studies with the highest
erythropoietin doses used, nevertheless still substantial
lower than those used in animal studies, and increasing
the dosage further would mean increasing the risk of
thromboembolic events due to elevated heamatocrit
levels [24]. On the other hand, we administered erythro-
poietin as soon as possible in our clinical setting, namely
immediately with PCI. However the average time from
symptom-onset to PCI was about 250 min, exceeding
the above mentioned critical time window limit of 4 h
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according to animal studies. Therefore, application of
erythropoietin even in advance to PCI or intracoronary
might be necessary to be protective and beneficial. The
recently published Intra-Co-EpoMI trial however failed
to demonstrate reduction of infarct size 3 months after
randomized intracoronary administration of a single
dose darbepoetin-alpha in STEMI patients [25]. Another
novel, promising approach to increase erythropoietin
doses and thereby prolong the therapeutic window with-
out increasing the thromboembolic risk, might be the
new erythropoietin derivates, which display no haemato-
poietic effects by preserved cardioprotection [26].
A central issue of the erythropoietin paradox however
might lay in the difference between animal models and
the real human world [27].
Erythropoietin mediated cardioprotective effects seem
to differ across species. While cardioprotection has been
clearly shown in ischemia-reperfusion models in small
rodents including mouse and rabbit, experiments in lar-
ger animals such as sheep and pig were either negative
or controversial [20, 21]. As mentioned above experi-
mental studies testing erythropoietin effects in myocar-
dial infarction mostly used healthy animals and
mimicked myocardial ischemia by mechanical injury of
the coronary artery. This basically contrasts the process
of MI in humans. Although MI is an acute phenomenon
it develops on the basis of atherosclerosis and is the final
stage of this chronic complex disease. STEMI patients
often experience periods of stable or unstable angina
with hypoxia and/or hypoperfusion and suffer from dif-
ferent degrees of congestive heart failure. Therefore, they
can exhibit pathologically elevated erythropoietin levels
leading to erythropoietin resistance. It has been shown,
that raised endogenous plasma erythropoietin concen-
trations in patients with congestive heart failure are as-
sociated with increased cardiovascular mortality [28].
This might also explain why we not only found no im-
provement of clinical outcome, but observed a trend to-
wards an increase in MACE following epoetin beta - a
trend we had already seen in the original REVIVAL 3
trial after 6 months of follow up. While 62–71% of our
study patients presented with multivessel disease, in the
current metaanalysis on patient level by Fokkema et al.
only 36% of the patients included had multivessel disease
indicating a less advanced, pronounced and preceded
disease process [11]. Therefore, Epoetin-ß therapy might
have encountered different endogenous erythropoietin
levels, resulting in the observed adverse outcome.
Separate analysis of patients in the upper and lower
quartile of baseline hemoglobin as an indirect estimate
of endogenous erythropoietin levels revealed no signifi-
cant impact of endogenous erythropoietin on efficiency
of exogen administered epoetin-ß in terms of death and
MACE - although a definitive conclusion can´t be
drawn, since the event numbers are too small. However
endogenous erythropoietin might not be the only
confounder present. Hypertension, diabetes, aging and
concomitant medication can also interfere with
erythropoietin-mediated cardioprotection in clinical set-
tings. Morphine, statins, ACE-inhibitors, angiotensin II
receptor blockers, antidiabetics and clopidogrel are
known to influence conditioning-induced cardioprotec-
tion and might overdrive or damp beneficial erythropoi-
etin effects [20].
The REVEAL study by Najjar et al. on 222 patients
with STEMI showed a higher incidence of death, MI,
stroke and stent thrombosis upon erythropoietin use
during the first 12 weeks. A subgroup analysis even re-
vealed increased infarct size among erythropoietin pa-
tients 70 years or older [29]. Although other studies on
erythropoietin in STEMI patients did not find an in-
creased risk of adverse events over the short term, side
effects of erythropoietin therapy are evident for other in-
dications like heart failure, renal disease, anemia or can-
cer [30, 31]. In patients with systolic heart failure and
anemia darbopoetin was accompanied by a significant
increase in thrombembolic events and septic shock [32].
Side effects have been linked to erythropoietin induced
increases in haematocrit, blood viscosity, blood pressure,
vasoconstriction or platelet function [33]. In the present
study the non-significant rise in adverse clinical events
after 5 years was mainly driven by more frequent target
vessel revascularization in response to epoetin beta. Cor-
responding quantitative coronary angiography after six
months revealed an increase in segment diameter sten-
osis in the epoetin beta group (32 ± 19% vs. 26 ± 14%, p
= 0.046). Despite a subtle induction of circulating pro-
genitor cells by erythropoietin, the observed increase in
neointima formation was not associated with progenitor
cell mobilization [13]. In a rat carotid artery model of
vascular injury erythropoietin induced excessive neoin-
tima formation [34]. Experimental studies in vascular le-
sions in mice are less clear: one study reported
inhibition of neointima hyperplasia due to enhanced
reendothelialisation by mobilized endothelial progenitor
cells and resident endothelial cells [35], while another
study described increased neointima formation upon
erythropoietin treatment due to enhanced smooth
muscle cell proliferation by paracrine effects of the
endothelium [36]. A clinical trial, designed to analyze
the effect of erythropoietin on restenosis, failed to dem-
onstrate, that short-term ‘low-dose’ epoetin beta pre-
vented neointimal hyperplasia in PCI-treated AMI
patients [37].
Our study is limited by the fact, that the REVIVAL-3
trial was powered to detect differences in left ventricular
ejection fraction and was not designed to evaluate effects
on long-term clinical outcomes. Although the relatively
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low number of patients enrolled precludes definitive
conclusions about clinical prognosis, we believe that the
herein presented data can provide nevertheless valuable
insights, since 97% of the study patients completed the
5-year clinical follow-up and it´s to date the only study
providing clinical outcome data more than 12 month
after epoetin treatment in AMI.
Conclusion
These 5 years follow-up data show that short-term use
of 3 IV doses epoetin beta in PCI-treated STEMI pa-
tients does not improve clinical long-term prognosis.
Our results further support the erythropoietin paradox
and advise caution regarding the application of erythro-
poetin in patients with STEMI.
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